These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 29676238

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers.
    Neves DV, Lanchote VL, Moysés Neto M, Cardeal da Costa JA, Vieira CP, Coelho EB.
    Br J Clin Pharmacol; 2016 Jul; 82(1):83-91. PubMed ID: 26914703
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype.
    García-Quetglas E, Azanza JR, Sádaba B, Muñoz MJ, Gil I, Campanero MA.
    Pharmacol Res; 2007 Feb; 55(2):122-30. PubMed ID: 17175164
    [Abstract] [Full Text] [Related]

  • 9. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers.
    Belmonte C, Ochoa D, Román M, Saiz-Rodríguez M, Wojnicz A, Gómez-Sánchez CI, Martín-Vílchez S, Abad-Santos F.
    Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):596-605. PubMed ID: 29325225
    [Abstract] [Full Text] [Related]

  • 10. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
    Abolfathi Z, Fiset C, Gilbert M, Moerike K, Bélanger PM, Turgeon J.
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1196-201. PubMed ID: 8371133
    [Abstract] [Full Text] [Related]

  • 11. Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response.
    Sowinski KM, Burlew BS.
    Pharmacotherapy; 1997 Sep; 17(6):1305-10. PubMed ID: 9399616
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Metabolism, pharmacokinetics, and excretion of a highly selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in human cytochrome P450 2D6 extensive and poor metabolizers.
    Johnson K, Shah A, Jaw-Tsai S, Baxter J, Prakash C.
    Drug Metab Dispos; 2003 Jan; 31(1):76-87. PubMed ID: 12485956
    [Abstract] [Full Text] [Related]

  • 17. No influence of CYP2D6*10 genotype and phenotype on the pharmacokinetics of nebivolol in healthy Chinese subjects.
    Luo X, Lei Y, He L, Liu W, Li M, Ran L, Yu M, Guo X, Yu P, Liu Z, Cheng Z.
    J Clin Pharm Ther; 2015 Oct; 40(5):561-565. PubMed ID: 26214065
    [Abstract] [Full Text] [Related]

  • 18. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
    Kirchheiner J, Heesch C, Bauer S, Meisel C, Seringer A, Goldammer M, Tzvetkov M, Meineke I, Roots I, Brockmöller J.
    Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
    Fux R, Mörike K, Pröhmer AM, Delabar U, Schwab M, Schaeffeler E, Lorenz G, Gleiter CH, Eichelbaum M, Kivistö KT.
    Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.